Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Watson consent decree

Executive Summary

Watson will hire an outside expert within 45 days to determine whether its "methods, facilities, and controls used at the Corona facility for manufacturing, processing, packing, holding, and distributing drugs are in compliance," the company's May 3 consent decree with FDA states. The first of the expert's annual reports is due in the first quarter of 2003. Watson has two pending ANDAs at the Corona, Calif. facility. As anticipated, Watson will not pay a fine or initiate a recall as a result of the consent decree (1"The Pink Sheet" April 1, p. 23)...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel